About Amal Therapeutics
AMAL Therapeutics SA is a spin-off from the University of Geneva
active in cancer immunotherapy.
AMAL has developed a unique protein-based immunization
platform called KISIMA® providing activation signal to dendritic
cells simultaneously to priming both helper and killer cells for
various antigens and HLA restrictions. This first-in-class platform is
offering the opportunity to develop standardized and indicationtailored
The company’s lead product ATP128 is currently being developed
for metastatic and advanced colorectal cancer.
State of Ownership
học viện thẩm mỹ prana, học viện thẩm mỹ prana